Abstract
Hypertension is a multifactorial condition characterized by persistently elevated blood pressure. In addition to genetic and environmental factors, recent studies suggest that the gut microbiota contributes to the development of hypertension and modulates the response to antihypertensive therapy. This review aims to summarize the latest knowledge on the bidirectional interaction between gut microbiota and antihypertensive drugs. Original studies published up to May 2025 on this topic were collected from two online databases: PubMed and Scopus. A total of 220 articles were identified, and 9 articles met the inclusion criteria for further discussion. Three of these included articles discussed how gut microbiota can interfere with the treatment process by metabolizing drugs into inactive or active forms before they reach their therapeutic targets. Whereas, six articles reported that antihypertensive medications can improve gut microbiota composition, increasing the abundance of specific bacterial taxa associated with blood pressure regulation. Overall, this review highlights the bidirectional relationship between gut microbiota and antihypertensive drugs, emphasizing potential clinical implications for personalized therapy. However, the small number of studies and their heterogeneity underline the need for cautious interpretation and further clinical validation.
Recommended Citation
Haq, Dhiya'Ul and Lestari, Keri
(2025)
"Crosstalk between Gut Microbiota and Antihypertensive Drugs: A Systematic Review,"
Pharmacology and Clinical Pharmacy Research: Vol. 10:
Iss.
3, Article 7.
Available at:
https://journal.unpad.ac.id/pcpr/vol10/iss3/7
Included in
Medical Pharmacology Commons, Other Pharmacology, Toxicology and Environmental Health Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons
